We are live on ! Find out more
MCRB icon

Seres Therapeutics

72 hedge funds and large institutions have $243M invested in Seres Therapeutics in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 27 increasing their positions, 15 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 15

77% more call options, than puts

Call options by funds: $165K | Put options by funds: $93K

0.01% more ownership

Funds ownership: 3.91%3.92% (+0.01%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

8% less funds holding

Funds holding: 7872 (-6)

11% less capital invested

Capital invested by funds: $274M → $243M (-$30.5M)

60% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 10

Holders
72
Holders Change
-6
Holders Change %
-7.69%
% of All Funds
1.65%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
4
Increased
27
Reduced
15
Closed
10
Calls
$165K
Puts
$93K
Net Calls
+$72K
Net Calls Change
-$192K
Name Holding Trade Value Shares
Change
Change in
Stake
BW
26
Bison Wealth
Georgia
$271K -$24.3K -150 -8%
Swiss National Bank
27
Swiss National Bank
Switzerland
$255K
California State Teachers Retirement System (CalSTRS)
28
California State Teachers Retirement System (CalSTRS)
California
$240K
Citadel Advisors
29
Citadel Advisors
Florida
$239K +$82.3K +509 +48%
DekaBank Deutsche Girozentrale
30
DekaBank Deutsche Girozentrale
Germany
$168K
JG
31
Jefferies Group
New York
$163K +$74.6K +461 +76%
CEP
32
Chicago Equity Partners
Illinois
$154K -$227K -1,404 -58%
IIM
33
Ironwood Investment Management
Massachusetts
$148K
PP
34
Paloma Partners
Connecticut
$147K +$157K +970 New
New York State Common Retirement Fund
35
New York State Common Retirement Fund
New York
$146K
ProShare Advisors
36
ProShare Advisors
Maryland
$145K -$5.18K -32 -3%
Two Sigma Advisers
37
Two Sigma Advisers
New York
$143K -$20.2K -125 -12%
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$138K -$10.7K -66 -7%
Connor, Clark & Lunn Investment Management (CC&L)
39
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$121K +$19.4K +120 +18%
Tudor Investment Corp
40
Tudor Investment Corp
Connecticut
$118K -$48.1K -297 -28%
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$114K
Millennium Management
42
Millennium Management
New York
$112K -$1.27M -7,871 -91%
AIG
43
American International Group
New York
$104K +$1.94K +12 +2%
ZIM
44
Zacks Investment Management
Illinois
$82K
Wells Fargo
45
Wells Fargo
California
$79K +$6.15K +38 +8%
CG
46
Cutler Group
California
$78K
VOYA Investment Management
47
VOYA Investment Management
Georgia
$77K
AG
48
Advisor Group
Arizona
$72K +$8.09K +50 +12%
Barclays
49
Barclays
United Kingdom
$60K +$45K +278 +242%
Citigroup
50
Citigroup
New York
$43K +$38.2K +236 +472%

MCRB Hedge Fund Activity: Q3 2018 in Review

72 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q3 2018, worth a combined $243M — down 11% from $274M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of MCRB and 4 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 27 added.

The largest buyer was ARK Investment Management, adding an estimated $6.26M. The largest seller was Vanguard Group, cutting an estimated $3.13M.

  • 72 institutional investors held Seres Therapeutics (MCRB) as of Q3 2018, down from 78 in Q2 2018.
  • Funds reported $243M of Seres Therapeutics stock for Q3 2018, down 11% quarter-over-quarter.
  • 4 funds opened new Seres Therapeutics positions in Q3 2018 and 10 closed out, a net change of -6 holders.
  • The largest Seres Therapeutics buyer in Q3 2018 was ARK Investment Management, an estimated $6.26M added.
  • The largest Seres Therapeutics seller in Q3 2018 was Vanguard Group, an estimated $3.13M sold.

Based on aggregated 13F filings for Q3 2018.